Radiosensitization of human gastrointestinal tumors by 5-fluorouracil (5-FU) has been studied in vitro and clinically in human cancer therapy trials. The bacterial enzyme cytosine deaminase (CD) converts the nontoxic prodrug 5-fluorocytosine (5-FC) into 5-FU. Human colon cancer cells stably expressing CD have been shown by other investigators to be sensitized to radiation following treatment with 5-FC. We previously used an adenoviral vector under control of the cytomegalovirus promoter (AdCMVCD) encoding the CD gene in combination with 5-FC and a single fraction of radiation exposure to enhance cytotoxicity to human cholangiocarcinoma cells in vitro and in vivo. The purpose of this study was to determine whether AdCMVCD infection and 5-FC with multiple fraction low-dose radiotherapy results in enhanced cytotoxicity. In the present study, we utilized AdCMVCD and 5-FC with single fraction radiotherapy to demonstrate enhanced cytotoxicity to WiDr human colon
Introduction
Radiotherapy combined with the radiosensitizing chemotherapeutic drug 5-fluorouracil (5-FU) has been studied as a therapeutic modality in many human tumor types. 1 Systemic toxicity limits the amount of 5-FU that can be administered for many clinical anticancer applications. 2, 3 Radiation therapy and gene therapy have the potential to be combined to enhance effectiveness of cancer therapy without enhancing dose-limiting toxicity. To this end, several reports have investigated this promising interaction.
carcinoma cells in vitro. Additionally, we tested this gene therapy/prodrug treatment strategy employing a fractionated radiation dosing schema in animal models of WiDr colon carcinoma and SK-ChA-1 cholangiocarcinoma. A prolonged WiDr tumor regrowth delay was obtained with AdCMVCD infection in combination with systemic delivery of 5-FC and fractionated external beam radiation therapy compared with control animals treated without radiation, without 5-FC, or without AdCMVCD. The results of treatment with AdCMVCD ϩ 5-FC ϩ radiation therapy to cholangiocarcinoma xenografts were equivalent to those obtained with systemic 5-FU administration ϩ radiation. Thus, the use of AdCMVCD can be effectively combined with clinically relevant 5-FC and radiation administration schemes to achieve enhanced tumor cell killing and increased control of established tumors of human gastrointestinal malignancies. Gene Therapy (2000) 7, 1019-1026.
verts a nontoxic prodrug 5-fluorocytosine (5-FC) into 5-FU. The CD gene has been used in gene therapy strategies to mediate intracellular conversion of 5-FC to 5-FU, and has been shown to be effective in animal tumor models of human colon carcinoma. 10 Human colon cancer cells that have been stably transduced to express the CD gene have been shown to be radiosensitized by the addition of 5-FC in vitro and in vivo. 7 Based on our prior experience, 8 we hypothesized that adenoviral delivery of CD with administration of 5-FC may be useful as a dual modality gene therapy/radiation therapy strategy for gastrointestinal cancers. The underlying premise is that high local concentrations of 5-FU can be generated by CD-expressing tumor cells, without accompanying systemic toxicity, to achieve chemotherapeutic radiosensitizing antitumor effects. Recently, our group has used an adenoviral vector encoding CD under control of the cytomegalovirus promoter (AdCMVCD) in combination with 5-FC and single fraction radiation treatment to demonstrate enhanced cytotoxicity against human cholangiocarcinoma cells in vitro and in vivo. 8, 11 Other investigators have shown that a retrovirus encoding CD and herpes simplex virus thymidine kinase in combination with 5-FC and ganciclovir with external beam radiation increased the killing of 9L gliosarcoma cells. 12 In the present study, AdCMVCD was used with 5-FC to achieve increased radiation killing of the WiDr colon cancer cell line both in vitro and in vivo. The conditions for optimal radiation enhanced killing were determined in vitro and the dose-response relationship was determined. Our previous studies defined these parameters for the SK-ChA-1 cholangiocarcinoma cell line, and a preliminary in vivo efficacy study was explored. 8 In the present study, in vivo models of colon and cholangiocarcinoma were evaluated for efficacy of gene therapy and low-dose fractionated radiotherapy, relevant for clinical applications. with virus and prodrug was used to normalize for the combination radiation survival values.
Results
AdCMVCD and 5-FC concentrations giving at least 90% killing alone were used in the radiation survival experiments. Percent survival following a single 8 Gy radiation dose following AdCMVCD infection at 1 and 10 MOI with increasing 5-FC concentrations is demonstrated for WiDr cells in Figure 2 . Enhanced radiation cytotoxicity was observed with increasing 5-FC concentrations at each MOI tested in WiDr cells. The maximal radiation enhanced cytotoxicity was observed at 1 and 10 MOI with 20 and 2 g/ml 5-FC, respectively.
The conditions that gave the greatest radiosensitization at 8 Gy for WiDr were used to establish a dose-response relationship ( Figure 3 ). The greatest increase in cell killing was observed with 1 MOI and 20 g/ml of 5-FC. The radiation survival curve parameters calculated using the linear quadratic and single hit multiple target (SHMT) models are listed in Table 1 Gy radiation is illustrated in Figure 4 . The enhanced effects of combined treatment were most evident at the 20 g/ml dose of 5-FC. A detailed radiation dose-response analysis has been published 8 and these prior studies demonstrated a D 0 = 0.968 and ␣ = 0.444 for the combined modality treatment of the SK-ChA-1 cholangiocarcinoma cells. The large value of ␣ and small D 0 indicate significant reduction in cell survival as a result of the combined treatments with low (2 Gy) and high (8 Gy) single frac- the AdCMVCD + 5 × 2 Gy groups (P = 0.0126 and 0.0121, respectively) ( Figure 6 ). The 5-FU + 5 × 2 Gy group also had a significantly longer time to tumor regrowth compared with the 5-FU alone and AdCMVCD + 5 × 2 Gy groups (P = 0.0204 and 0.0180, respectively).
In the tumors that were not injected with the AdCMVCD virus, no areas of CD expression were identified (Figure 7a) . In all tumors transfected (X1) with AdCMVCD, focal areas of CD expression were detected by immunohistochemistry (data not shown). Frequently, these areas had immediately adjacent areas of subacute necrosis and granulation tissue. In all the animals receiving transfection (X3) with AdCMVCD, focal areas of CD expression were identified (Figure 7b and c) . In two of the three mice of this second group, areas of expression of CD were more extensive than in the mice receiving AdCMVCD in one injection; similarly, the areas of subacute and acute necrosis adjacent to tumor with CD expression were more extensive. 
Discussion
The use of gene transfer methods employing adenoviral vectors to sensitize cells to the effects of ionizing radiation holds promise for solid tumor therapy. The results of this study show that an adenovirus encoding the CD gene used with the prodrug 5-FC can lead to enhanced cell killing when used in combination with ionizing radiation in vitro and in vivo for two human gastrointestinal malignancies, colon carcinoma and cholangiocarcinoma. Our previous studies in human cholangiocarcinoma 8, 11 demonstrated the in vitro radiosensitizing effects of combining CD transgene expression with 5-FC prodrug treatment and single fraction radiation therapy. The survival of SK-ChA-1 cells in the present study treated with AdCMVCD + 5-FC + 8 Gy radiation in vitro was similar to that previously reported. 8 The radiobiological parameters derived from the clonogenic assay in this study describe the extent of killing of WiDr cells induced by the combined treatment. The small D 0 and non-zero ␣ values obtained for the combination treatment groups indicate cytotoxic effects both at high and low radiation doses for the WiDr colon cancer cells, which is similar to what was observed with the SK-ChA-1 cholangiocarcinoma cells. The non-zero ␣ value for AdCMVCD at MOI 1 and 10 with 20 or 2 g/ml 5-FC indicates significant cytotoxicity in the low (2 Gy) radiation dose region. This result indicates that multifraction treatment in this clinically relevant low-dose region would be effective. The smallest D 0 values which indicate greatest radiation cytotoxicity in the high-dose region were obtained with the AdCMVCD + 5-FC combined treatment groups. The AdCMVCD at MOI 10 and no 5-FC had an intermediate D 0 value suggesting some radiosensitization by the higher dose of AdCMVCD. We have observed previously some radiosensitization by high-dose AdCMVCD infection alone with SK-ChA1 cells. 8 The significance of this observed effect remains uncertain but may be relevant in human cancer gene therapy applications.
From the encouraging results of the in vitro evaluation of induction of radiosensitivity for both colon cancer and cholangiocarcinoma cells, in vivo models were evaluated. For SK-ChA-1 cholangiocarcinoma tumors, our previous study showed an enhanced antitumor effect of combined AdCMVCD infection, 5-FC administration, and a single Gene Therapy 10 Gy radiation dose compared with AdCMVCD infection and 5-FC alone. Radiation therapy in the clinical setting is traditionally delivered in daily 2 Gy doses over 6-8 weeks. We investigated more clinically relevant lowdose multifraction regimens (2 or 5 Gy per fraction over 1 week) as an initial test of fractionated treatment. Analysis of this format of radiation therapy and CD/5-FC gene therapy with human colon cancer and cholangiocarcinoma indicated the fractionated delivery of 3 × 5 Gy doses or 5 × 2 Gy doses was at least as effective as a single 10 Gy fraction or with systemically administered 5-FU and 5 × 2 Gy doses. Thus, a measurable antitumor effect was observed with CD/5-FC gene therapy in combination with low-dose fractionated radiation therapy. Escalation of combined treatment over a 6-8 week period clinically might increase the duration of the observed antitumor effect, but would be difficult to carry out in the animal model.
Khil et al 7 showed that the CD gene stably transfected into WiDr cells was able to enhance radiation cell killing in vitro. Adenoviral vectors have been used in many gene transfer and therapy studies. The use of adenoviral vectors to encode CD and convert 5-FC to 5-FU to achieve cell killing has been reported. 13, 14 Ohwada et al 15 delivered an adenoviral vector encoding CD into normal tissue 0.8-1 cm from the site of colon tumor xenografts in the liver of mice and systemically delivered 5-FC to suppress metastatic tumor growth. Therefore, there is potential that treatment of primary tumor nodules with the combination of 5-FC conversion to 5-FU by the CD enzyme and radiation could lead to increased local control while the production of 5-FU would serve to suppress metastatic growth.
Both metastatic colon carcinoma and locally advanced cholangiocarcinoma are difficult clinical problems, and have been resistant to therapy with a single modality. 2, 16, 17 The gene therapy approach of molecular chemotherapy combined with radiation therapy provides a new approach to the treatment of solid tumors. The ability of 5-FC and 5-FU to diffuse freely across cell membranes is one advantage of the CD/5-FC toxin gene/prodrug strategy. This is in contrast to the HSVtk/GCV system where cellular gap junctions are a vital component of the bystander effect. 18, 19 Another advantage of CD/5-FC demonstrated here with respect to the WiDr colon cancer model was efficacy at a very low viral concentration of 1 MOI. A MOI of 1 with a high 5-FC concentration (20 g/ml) was more effective than a MOI of 10 and a low 5-FC concentration (2 g/ml). This is an important observation since it may be difficult to achieve 100% infection of cells in solid tumors in situ. Our in vivo studies lend support to the possibility that less than 100% tumor infection can be effective. Although it is likely that only a fraction of tumor cells in the xenografts were infected as demonstrated by the immunohistochemistry results, a significant regrowth delay was observed in the irradiated, AdCMVCD-infected tumors treated with 5-FC compared with irradiation alone or the AdCMVCD-infected and 5-FC-treated tumors without irradiation. An important observation was that low-dose multifraction radiation treatment in combination with CD/5-FC gene therapy was effective in inhibiting tumor growth. The ability to achieve greater regrowth delay with combined modality therapy with an adenoviral vector in vivo demonstrates the potential of this cancer gene therapy strategy as a treatment modality that can be tested in human clinical trials.
Materials and methods

Cell culture
The human colon carcinoma cell line WiDr (ATCC, Rockville, MD, USA) was grown in Earle's modified Eagle's medium (EMEM) (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Summit, Fort Collins, CO, USA), 2 mm glutamine, and 1% non-essential amino acids in a humidified atmosphere with 5% CO 2 . The human cholangiocarcinoma cell line SK-ChA-1 was the gift of A Knuth (Ludwig Institute for Cancer Research, London, UK). SK-ChA-1 cells were maintained in RPMI-1640 medium supplemented with 2 mm l-glutamine and 10% FBS at 37°C in a humidified 5% CO 2 atmosphere. The transformed human embryonal kidney cell line, 293, is an E1A transcomplementing cell line (Microbix, Toronto, Canada) utilized for viral propagation and titering and was maintained in Dulbecco's modified Eagle's medium-F12 supplemented with 2 mm l-glutamine and 10% FBS at 37°C in a humidified 5% CO 2 atmosphere. The cells were passaged using 0.05% trypsin and 5 mm EDTA once weekly.
Chemotherapeutic drugs 5-FC (Sigma, St Louis, MO, USA) was dissolved in PBS at a stock concentration of 10 mg/ml. 5-FU (50 mg/ml, Hoffman-LaRoche, Nutley, NJ, USA) was used as a control for standard clinical therapy of both colon and cholangiocarcinoma in current medical practice.
Adenovirus production and characterization
The production, characterization, and functional validation of the AdCMVCD vector was described previously. 8, 11 Briefly, the CD gene was cloned into the adenoviral shuttle vector pACCMVpLpARS (+) (provided by R Gerard, Katholieke Universiteit Leuven, Ontario, Canada) and then cotransfected with the pJM17 rescue plasmid (kindly provided by Dr F Graham, McMaster University) into 293 cells to allow for homologous recombination. 20 Individual plaques were isolated and subjected to two further rounds of plaque purification. The final adenovirus was validated by PCR and restriction analysis. The ability of AdCMVCD to induce a functional CD enzyme was determined using an assay to measure conversion of 3 H-5-FC to Co radiation; and (4) AdCMVCD, 5-FC and no radiation. The AdCMVCD vector was injected intratumorally (i.t.) once every other day for a total of three injections beginning at day −2 relative to radiation. The 5-FC was administered for 7 days as 500 mg/kg twice daily by i.p. injection beginning at day −2 relative to radiation. Two days following the initial adenoviral and 5-FC injection, mice were anesthetized with ketamine-HCl (Phoenix Scientific, St Joseph, MO, USA) and irradiated. The first 5 Gy fraction was given followed by two subsequent 5 Gy fractions given daily. The 10 Gy single dose was given on the same day as the second 5 Gy fraction.
The SK-ChA-1 tumor treatment groups included: (1) AdCMVCD, 5-FC, and 5 × 2 Gy; (2) AdCMVCD, 5-FC, without radiation; (3) 5-FU (30 mg/kg/day as 15 mg/kg twice daily) without radiation; (4) 5 × 2 Gy radiation and 5-FU (30 mg/kg/day as 15 mg/kg twice daily); and (5) no treatment. The mice with SK-ChA-1 tumors received 5-FC (400 mg/kg twice daily by i.p. injection) beginning at day −2 relative to radiation therapy, and continued for 7 days. The mice were anesthetized with ketamine-HCl, and their tumors irradiated using the Picker 60 Co therapy unit. All mice were shielded with a specially designed lead apparatus that allowed irradiation of a single flank (six mice at a time). Tumor growth was measured three times weekly in two dimensions using a Vernier caliper and the tumor size (length × width) was calculated. The animals were maintained in a laminar flow room and fed sterilized chow and tap water in accordance with University of Alabama Animal Resource Department protocols.
Immunohistochemistry
Our methods for performing immunohistochemistry have been documented extensively in the literature. [21] [22] [23] [24] In brief our methods are as follows.
Paraffin sections of control untreated WiDr tumors or tumors that were injected i.t. ×1 or once every other day for a total of three injections of AdCMVCD vector in animals administered 5-FC for 7 days at 500 mg/kg twice daily by i.p. injection beginning on the first day of AdCMVCD injection were cut at 4 m, mounted on sialinized slides (Plus slides), and melted at 58°C in an oven for 1 h. The paraffin was removed from the sections with three changes of xylene for 5 min each, followed sequentially by absolute ethanol, 95% ethanol, 70% ethanol and Tris buffer. Endogenous peroxidase was quenched using a fresh aqueous solution of 3% peroxide. Goat serum (1%) was then added to the tissue section for 20 min in order to block nonspecific immunostaining. To reduce interference from endogenous mouse antibodies BEAT blocking solutions A and B (50-300 Histomouse blocking reagents; Zymed, San Francisco, CA, USA) were used. Sections were then incubated for 1 h with the mouse monoclonal primary antibody to CD 25 at a concentration of 0.25 g/ml.
Our secondary detection system for monoclonal antibodies uses an anti-mouse detection system from Biogenex (ZP00-UM StrAviGen Supersensitive, Biogenex Laboratories, San Ramon, CA, USA). After the excess primary antibody was washed from the tissue section with Tris buffer and the sections soaked in Tris buffer for 5 min, the sections were incubated with biotinylated goat anti-mouse antibody (1:40 dilution, Biogenex) for 20 min. The sections then were washed with Tris buffer followed by 5 min of soaking in Tris buffer. Next the sections were covered with peroxidase-labeled streptavidin (Biogenex, 1:40 dilution) for 20 min followed by a 5 min wash-soak in Tris buffer. The chromogen, 3,3Ј-diaminobenzidine (DAB), at 1 mg/ml in Tris buffer with 0.016% fresh H 2 O 2 was added for 4 min. The DAB was washed from the slides with deionized water. A light hematoxylin counterstain was used to demonstrate the tumor architecture.
Statistical methods
The logrank test was used to assess if there were differences among the four groups of animals bearing WiDr Gene Therapy xenografts in overall survival, time to tumor doubling, and time to regrowth. Time to event analysis allows for the inclusion of a censoring variable that indicates whether the event of an interest has occurred or not, thus all animals were included in the analysis. Specific pairwise comparisons between treatment groups for time to tumor regrowth and time to tumor doubling were also made using the logrank test. Fisher's Exact test was used to assess if there were any differences in tumor regression rate between groups.
The logrank test was used to assess if there were differences among the five groups of animals bearing SK-ChA-1 xenografts in time to tumor doubling and time to regrowth. Specific pairwise comparisons were made between treatment groups for time to tumor regrowth due to lack of an overall difference in time to tumor doubling. The level of significance used for all comparisons was P Ͻ 0.05.
